PCN358 DEMOGRAPHIC, CLINICAL CHARACTERISTICS, TREATMENT PATTERNS AND CLINICAL OUTCOMES BY LINES OF TREATMENT IN HR+/HER2− ADVANCED BREAST CANCER IN COLOMBIA

Sandra Franco(Clínica Santa María), J.M. Reyes Sanchez, Maria E. Montoya(Instituto de Cancerología Las Américas), José Lobatón, G.A. Matiz, Brigitte Alejandra Alarcon, Gabriela Marchena Rojas, Sandra Aruachán, Samantha K. Kurosky(Triangle), N. Castaño Gamboa(Pfizer (United Kingdom)), P.A. Londoño
Value in Health
May 1, 2020
10.1016/j.jval.2020.04.1813
Cited by 0

Related Papers

A phase II, open-label, multicenter study of GW572016 in patients with trastuzumab-refractory metastatic breast cancer
|Journal of Clinical Oncology|2004|90
A phase II, open-label, multicenter study of GW572016 in patients with trastuzumab-refractory metastatic breast cancer
|Journal of Clinical Oncology|2004|44
Uptake, Coverage, and Completion of Quadrivalent Human Papillomavirus Vaccine in the Vaccine Safety Datalink, July 2006–June 2011
|Journal of Adolescent Health|2013|21
Guía de práctica clínica para la prevención, detección temprana, diagnóstico, tratamiento y seguimiento de las dislipidemias en la población mayor de 18 años
|Unknown|2014|12
Investigation of tumor biomarkers as response predictors in a monotherapy study with lapatinib (L) as a first line treatment in ErbB2 amplified women with breast cancer
|Journal of Clinical Oncology|2007|11